1009 related articles for article (PubMed ID: 9435993)
21. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
van Harten J
Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
[TBL] [Abstract][Full Text] [Related]
22. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Hemeryck A; Belpaire FM
Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
[TBL] [Abstract][Full Text] [Related]
23. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.
Taylor D
Br J Psychiatry; 1995 Nov; 167(5):575-80. PubMed ID: 8564311
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics and drug interactions of antidepressive agents].
Sawada Y; Ohtani H
Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
[TBL] [Abstract][Full Text] [Related]
25. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
[TBL] [Abstract][Full Text] [Related]
26. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):309-14. PubMed ID: 10445388
[TBL] [Abstract][Full Text] [Related]
27. Clinically significant drug interactions with antidepressants in the elderly.
Spina E; Scordo MG
Drugs Aging; 2002; 19(4):299-320. PubMed ID: 12038880
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
Caccia S
Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
Sánchez C; Hyttel J
Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
[TBL] [Abstract][Full Text] [Related]
30. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.
Lane RM
Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():31-61. PubMed ID: 9032002
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic optimisation of therapy with newer antidepressants.
Goodnick PJ
Clin Pharmacokinet; 1994 Oct; 27(4):307-30. PubMed ID: 7834966
[TBL] [Abstract][Full Text] [Related]
33. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
Gregor KJ; Way K; Young CH; James SP
J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
[TBL] [Abstract][Full Text] [Related]
34. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.
Caraci F; Crupi R; Drago F; Spina E
Curr Drug Metab; 2011 Jul; 12(6):570-7. PubMed ID: 21395523
[TBL] [Abstract][Full Text] [Related]
35. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
36. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
J Pharm Pharmacol; 2001 Apr; 53(4):449-61. PubMed ID: 11341361
[TBL] [Abstract][Full Text] [Related]
37. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
38. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
Edwards JG; Anderson I
Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
[TBL] [Abstract][Full Text] [Related]
40. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
